Close Menu

cervical cancer

The German firm said that researchers can now run its GynTect cervical cancer assay on Roche Diagnostics' Cobas z 480 analyzer.

The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.

The firms said that HuaSin obtained exclusive rights to develop a fully automated HPV genotyping assay platform that uses Genomica’s technology.

In a newly published study, an algorithm developed at NIH shows promise for improving early detection of cervical cancer in low-resource areas, where 80 percent of cases occur.

Developers of POC STI platforms and assays said that the tests provide convenience, privacy, and quick results in an area of testing in need of these benefits.

Called CerMark, the test is aimed at women in resource-constrained settings and will measure proteins linked to HPV infection and cervical disease progression.

The a single-tube, multiplex real-time PCR-based MeltPro High Risk HPV test identifies 14 high-risk genotypes of human papillomavirus  and was previously CE marked.

The so-called enVision HPV test performed well in a comparison to Roche's Cobas HPV assay, and the Singapore researchers are considering other test applications.

The probes are for use in Cancer Genetics' FISH-based HPV-Associated Cancer Test, which measures genomic changes to help triage cervical cancer patients.

Physicians can now use the Dako PD-L1 IHC 22C3 pharmDx assay to identify urothelial carcinoma patients who may benefit from the anti-PD1 immunotherapy.

Pages